Serum nesfatin-1 levels are decreased in pregnant women newly diagnosed with gestational diabetes
Arch. endocrinol. metab. (Online); 61 (5), 2017
Publication year: 2017
ABSTRACT Objective To investigate serum nesfatin-1 levels at 24-28 weeks of pregnancy in women newly diagnosed with gestational diabetes and determine the association of nesfatin-1 with several metabolic parameters. Subjects and methods Forty women newly diagnosed with gestational diabetes at 24-28 weeks of pregnancy and 30 healthy pregnant women matched in age and gestational week were included in this cross-sectional study. Serum nesfatin-1 levels were analyzed using ELISA, and the relationship between nesfatin-1 and several metabolic parameters were assessed. Results Serum nesfatin-1 levels were found to be lower in women with gestational diabetes compared to the pregnant women in the control sample (p = 0.020). Multiple linear regression analysis revealed that nesfatin-1 was lower in participants with gestational diabetes independently from gestational age, BMI, HOMA-IR, fasting plasma glucose, and age. In correlation analysis, the only variable that was found to have a statistically significant correlation with nesfatin-1 was gestational age (p = 0.015, r = 0.30). Conclusion Lower nesfatin-1 levels in women with gestational diabetes compared to the control group at 24-28 weeks of gestation draws attention to nesfatin-1 levels in gestational diabetes and motivates further research in this area.
Biomarcadores/sangre, Índice de Masa Corporal, Proteínas de Unión al Calcio/sangre, Estudios de Casos y Controles, Estudios Transversales, Proteínas de Unión al ADN/sangre, Diabetes Gestacional/sangre, Diabetes Gestacional/diagnóstico, Ensayo de Inmunoadsorción Enzimática, Ayuno/sangre, Edad Gestacional, Prueba de Tolerancia a la Glucosa, Proteínas del Tejido Nervioso/sangre, Nucleobindinas